1346599-86-7
Chemical Structure
Blonanserin-d5
Synonym(s): AD-5423-d5
- CAS No.: 1346599-86-7
- Formula:C23H25D5FN3
- Molecular Weight:372.53
IUPAC Name: 2-(4-(ethyl-d5)piperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine
InChIKey: XVGOZDAJGBALKS-ZBJDZAJPSA-N
SMILES: FC1=CC=C(C2=C(CCCCCC3)C3=NC(N4CCN(C([2H])([2H])C([2H])([2H])[2H])CC4)=C2)C=C1
Biological Activity: Blonanserin-d5 (AD-5423-d5) is a deuterium labeled Blonanserin (HY-13575). Blonanserin is a dopamine D2/5-HT2 receptor antagonist and an atypical antipsychotic[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Blonanserin-d5 | Blonanserin-d5 (AD-5423-d5) is a deuterium labeled Blonanserin (HY-13575). Blonanserin is a dopamine D2/5-HT2 receptor antagonist and an atypical antipsychotic. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Blonanserin (Standard) | ≥98% | Blonanserin (Standard) is the analytical standard of Blonanserin. This product is intended for research and analytical applications. Blonanserin (AD-5423) is a potent and orally active 5-HT2A (Ki=0.812 nM) and dopamine D2 receptor (Ki =0.142 nM) antagonist. Blonanserin is usually acts as an atypical antipsychotic agent and can be used for the research of extrapyramidal symptoms, excessive sedation, or hypotension. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Blonanserin-d8 | Blonanserin-d8 is a deuterium labeled Blonanserin. Blonanserin is a dopamine D2/5-HT2 receptor antagonist and an atypical antipsychotic. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Blonanserin | 99.91% | Blonanserin (AD-5423) is a potent and orally active 5-HT2A (Ki=0.812 nM) and dopamine D2 receptor (Ki =0.142 nM) antagonist. Blonanserin is usually acts as an atypical antipsychotic agent and can be used for the research of extrapyramidal symptoms, excessive sedation, or hypotension. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Tenjin, T., et al., Profile of blonanserin for the treatment of schizophrenia. Neuropsychiatr Dis Treat, 2013. 9: p. 587-94. [Content Brief]
- [2]. Oka, M., et al., Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J Pharmacol Exp Ther, 1993. 264(1): p. 158-65. [Content Brief]